Drug	Typical Dosing

Itraconazole Sporanox^® Pregnancy: C; Lactation: Unsafe Caps: 100 mg Oral Solution: 100 mg/10 mL	Children: 5 mg/kg/day (max 100 mg/day) once daily for 4-6 weeks. Limited
	information on use in children. Avoid if possible.
	Using 100 mg/10 mL @ 5 mg/kg/day
	5 kg (11 lb) = 2.5 mL Q24H
	10 kg (22 lb) = 5 mL (1 tsp) Q24H
	15 kg (33 lb) = 7.5 mL Q24H
	25 kg (55 lb) = 10 mL (2 tsp) Q24H or 100-mg cap
	Adult: 100-600 mg/day in one to three divided doses (usual maximum 200 mg/dose).
	Food: Avoid grapefruit products while taking. Take capsules with food, and take oral solution on an empty stomach.
	Important side effects: Headache, dizziness, rash, vomiting, diarrhea, hypertension, hypokalemia, cardiac arrhythmias, elevated LFTs, hepatitis. Advise patient to report any prodromal signs of liver failure (fatigue, weakness, nausea, vomiting, yellowing of eye(s) or skin).
	Caution: May cause hepatitis. Use with caution in persons with history of liver disease. Consider periodic liver function tests. May cause or contribute to congestive heart failure or cardiac dysrhythmias. Use with caution in persons with history of cardiac disease. Use for onychomycosis is contraindicated in patients with history of ventricular dysfunction or CHF. Use is contraindicated in any patient taking cisapride, dofetilide, quinidine, midazolam, triazolam, pimozide, lovastatin, or simvastatin. Not well absorbed with acid-suppressing drug. Has caused bone defects and changes in tooth appearance in rats; implications for humans are not established.
	Drug interactions may be common and significant, including: Cisapride (avoid), alfentanil, benzodiazepines, buspirone, calcium channel blockers, carbamazepine, corticosteroids, cyclosporine, digoxin, dofetilide, haloperidol, HMG-CoA reductase inhibitors, phenytoin, oral hypoglycemics, pimozide (avoid), protease inhibitors, rifamycin, quinidine, tacrolimus, tolterodine, vinca alkaloids, warfarin, acid-suppressing drugs and antacids. Women of child-bearing age should use an effective form of contraception during and for 1 month after therapy.